JPMorgan raised the firm’s price target on Evolent Health to $45 from $36 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on EVH: Texas probes CenterPoint, Starbucks in talks with Elliott: Morning Buzz Expedia beats, Paramount cuts staff: Friday Buzz Expedia reports Q2 beat, Paramount to cut staff: Morning Buzz Evolent Health rises 32.8% Evolent Health rises 31.0%
